tbuckley/cabot-search huggingface dataset:
<i>Notes from the Field: Clostridium perfringens</i>Gastroenteritis Outbreak Associated with a Catered Lunch — North Carolina, November 2015
Authors: Jessica L. Rinsky, E. Berl, V. Greene, J. Morrow, A. Didomenico, J. MacFarquhar, G.A. Gómez, C. Lúquez, C. Williams
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

During November 2015, the North Carolina Division of Public Health was notified by the Pitt County Health Department (PCHD) that approximately 40 persons who attended a catered company Thanksgiving lunch the previous day were ill with diarrhea and abdominal pain. The North Carolina Division of Public Health and PCHD worked together to investigate the source of illness and implement control measures. Within hours of notification, investigators developed and distributed an online survey to all lunch attendees regarding symptoms and foods consumed and initiated a cohort study. A case of illness was defined as abdominal pain or diarrhea in a lunch attendee with illness onset <24 hours after the event. Risk ratios (RRs) and 95% confidence intervals (CIs) were estimated for all menu items. Among 80 attendees, 58 (73%) completed the survey, including 44 respondents (76%) who reported illnesses meeting the case definition; among these, 41 (93%) reported diarrhea, and 40 (91%) reported abdominal pain. There were no hospitalizations. Symptom onset began a median of 13 hours after lunch (range = 1-22 hours). Risk for illness among persons who ate turkey or stuffing (38 of 44; 86%), which were plated and served together, was significantly higher than risk for illness among those who did not eat turkey or stuffing (six of 14; 43%) (RR = 2.02; 95% CI = 1.09-3.73).
AB0158 The Expression of Blimp-1 in B Cells in Peripheral Blood from Patients with SLE and Its Clinical Significance
Authors: M. Wang, Y. Zhou, L. Jin, X. Fang, X. Li, G. Wang, X. Li
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To detect the mRNA expression of B lymphocyte induced maturation protein-1 (Blimp-1) in CD19<sup>+</sup> B cells in peripheral blood of patients with systemic lupus erythromatosus (SLE) and healthy controls, and explore its clinical significance. <h3>Methods</h3> Expression level of Blimp-1 mRNA in CD19 <sup>+</sup>B cells in peripheral blood was determined by real-time PCR in 40 SLE patients and 20 healthy controls. The ratio of CD19<sup>–</sup>CD138<sup>+</sup> plasma cells to CD19<sup>+</sup> B cells and the ratio of CD19<sup>+</sup>CD27<sup>+</sup> memory B cells to CD19<sup>+</sup> B cells were studied by flow cytometry in peripheral blood of two groups. <h3>Results</h3> 1. The expression level of Blimp-1 mRNA in CD19<sup>+</sup> B cells in peripheral blood od SLE patients was higher than that in healthy controls (<i>P</i>&lt;0.05), and the expression level of Blimp-1 in active SLE patients was higher than that in inactive SLE patients (<i>P</i>&lt;0.05). 2. The CD19<sup>–</sup>CD138<sup>+</sup> plasma cells/CD19<sup>+</sup> B cells ratio was increased in SLE patients compared to healthy controls (<i>P</i>&lt;0.01), and the CD19<sup>–</sup>CD138<sup>+</sup> plasma cells/CD19<sup>+</sup> B cells ratio in active SLE patients group was higher than that in inactive SLE patients (<i>P</i>&lt;0.05). However, the CD19<sup>+</sup>CD27<sup>+</sup> memory B cells/CD19<sup>+</sup> B cells ratio showed no significantly different between SLE patients and healthy controls (<i>P</i>&gt;0.05). 3. The expression level of Blimp-1 was positive correlated with the CD19<sup>–</sup>CD138<sup>+</sup> plasma cells/CD19<sup>+</sup> B cells ratio (<i>r</i><sub>s</sub>=0.336, <i>P</i>=0.034), positive correlated with anti-dsDNA antibody and immunoglobulin G (<i>r</i><sub>s</sub>=0.493, <i>P</i>=0.006; <i>r</i><sub>s</sub>=0.527, <i>P</i>=0.004), positive correlated with anti-nucleosome antibody and anti-C1q antibody (<i>r</i><sub>s</sub>=0.452, <i>P</i>=0.040; <i>r</i><sub>s</sub>=0.522, <i>P</i>=0.015), negative related with white blood cell count and platelet count (<i>r</i><sub>s</sub>= -0.367, <i>P</i>=0.046; <i>r</i><sub>s</sub>= -0.386, <i>P</i>=0.035). <h3>Conclusions</h3> The expression of Blimp-1 was up-regulated in SLE patients and significantly correlated with plasma cells, which suggests that Blimp-1 may be involved in the pathogenesis of SLE by promoting plasma cells differentiation. <h3>Acknowledgement</h3> This work was funded by a grant from the National Nature Science Foundation of China (No. 81373187) and the Clinical Research Special Foundation of Chinese Medical Association (12040730373). <h3>Disclosure of Interest</h3> None declared
PTU-047 Anti-CD3 Antibody Induces T-Cell Mediated Apoptosis and Shedding of Murine Small Intestinal Epithelial Cells
Authors: AH Elramli, CA Duckworth, BJ Campbell, DM Pritchard
Journal: Gut (2016)

<h3>Introduction</h3> Anti-CD3 antibody binds to the CD3/TCR complex on the wall of T lymphocytes and results in their activation. This leads to the release of various cytokines including tumour necrosis factor (TNF). TNF has previously been shown to bind to the TNFR1 receptor on the basolateral wall of small intestinal epithelial cells (IECs), triggering their apoptosis and shedding (Williams JM <i>et al</i>, DMM, 2013). We aimed to determine the time course and dose response of anti-CD3 antibody-induced apoptosis in murine small IECs and investigate whether this is regulated by the expression of members of the NFκB family of proteins. <h3>Methods</h3> Groups of 3 wild-type female C57BL/6 J mice were injected intraperitoneally (i.p.) with 1 mg/kg anti-CD3 antibody and were euthanased at different time-points from 1–6 hours. Groups of 3 wild-type female C57BL/6 J were subsequently injected i.p. with 0.5–4 mg/kg anti-CD3 antibody and were killed after 1.5 hours. The responses of 6 NFκB1<sup>-/-,</sup>6 NFκB2<sup>-/-</sup> and 6 c-Rel<sup>-/-</sup> female mice were compared with 6 C57BL/6 mice 1.5 hours after i.p. administration of 2 mg/kg anti-CD3 antibody. After euthanasia, the small intestine was dissected, fixed in formalin and paraffin embedded to produce histological slides. Immunohistochemistry was performed using a rabbit anti-mouse active caspase 3 primary antibody. Positively stained cells reflecting the percentage of shedding and apoptotic cells were scored on 20 villi per mouse on a cell positional basis. Data are expressed as mean ± SEM. Statistical analysis was performed using one-way ANOVA (with Tukey post-hoc test for multiple comparisons). p &lt; 0.05 was considered significant. <h3>Results</h3> 1 mg/kg anti-CD3 antibody caused a significant increase in the percentage of IECs undergoing apoptosis and shedding from 1±0.1% in untreated mice to a peak of 2.3±0.1% at 1.5 hours then started to decline to reach 1.3±0.1% at 6 hours. The percentage of IECs undergoing apoptosis and shedding increased with increasing doses of anti-CD3 antibody with a maximum of 5.6±0.2% observed 1.5 hours after administration of 4 mg/kg anti-CD3 antibody. Although NFκB1<sup>-/-</sup> mice (5.1±0.3%) and c-Rel<sup>-/- </sup>mice (4.8±0.6%) showed more IEC apoptosis and shedding than wild-type (3.6±0.2%) these differences were not significant. However NFκB2<sup>-/-</sup> mice were much more resistant (0.8±0.1%) (p &lt; 0.001). In all cases the effects of anti-CD3 antibody were most pronounced in the apical portion of small intestinal villi. <h3>Conclusion</h3> Systemic administration of anti-CD3 antibody induces apoptosis and shedding of murine IECs. The time course and cell positional distribution of apoptotic cells are very similar to those observed following administration of either lipopolysaccharide or TNF. The responses to anti-CD3 antibody are significantly affected by the expression of NFκB2. <h3>Disclosure of Interest</h3> None Declared
PTU-122 A National Survey of GI Physiology &amp; Motility Services in The UK and Ireland
Authors: DH Vasant, S Hamdy, K Solanki, S Senapati, L Smith, J Barlow, NV Radhakrishnan
Journal: Gut (2016)

<h3>Introduction</h3> Clinical demands and advances in diagnostics and therapeutics have seen a rapid growth in GI physiology/motility services. We surveyed the practice, training and attitudes towards services nationally, to determine if these aspects have kept pace with expansion and to identify areas for development. <h3>Methods</h3> An online survey developed by a multi-disciplinary panel with medical, surgical and GI physiology representation was circulated to all GI clinicians and physiologists in the UK &amp; Ireland by their national societies BSG, AGIP, AUGIS and ACPGBI. The survey included both generic questions and specific ones signposted for ‘specialists’ (GI physiologists/clinical leads). <h3>Results</h3> 313 responses (59% Gastroenterologists) were received, with 221/313 (71%) from 98 institutions having an on-site GI physiology unit. Most units (88/98) had a clinical lead (60% Gastroenterologists, 34% with ‘subspecialty interest’). Figure 1 summarises the services available nationally. GI physiologists/nurse specialists conduct the majority of studies (69%) and biofeedback (84%). GI physiologists report most studies (Upper GI 71%, Lower GI 69%), however cases are often discussed with a lead clinician prior to finalising (Upper GI: 34% discuss all cases and 38% selected cases; Lower GI: 27% discuss all cases and 27% selected cases), 45% have dedicated multidisciplinary team meetings (MDT) for reporting (held weekly in 72%) and of those without an MDT, 72% felt introducing one would improve provision of therapeutic recommendations. 54% of ‘specialists’ reported that therapeutic recommendations are not routinely made (50% citing reasons such as; no subspecialist clinician/ ‘not qualified’ or ‘not necessary’). Moreover, 70% of ‘specialists’ felt a ‘subspecialist’ clinician is best placed to make such recommendations, whilst only 4% of clinicians without subspeciality interest are comfortable interpreting the data. Overall, very few felt that services (26%), research opportunities (15%) and training (14% for GI physiologists and 10% for clinicians) were adequate, with most GI physiologists (83%) and clinicians (96%) recommending changes with suggestions including an accredited clinical training programme. <h3>Conclusion</h3> The survey highlights that GI physiology/motility is a rapidly emerging sub-specialty with limited exposure during clinical training. An MDT approach with subspecialist clinical input facilitates interpretation of complex data and provision of therapeutic recommendations. Percieved deficiencies in current services and training systems have been identified, providing an opportunity to raise awareness nationally via AGIP/BSG and to build on existing training pathways. <h3>Disclosure of Interest</h3> None Declared
Type I Methemoglobinemia Caused by the Cytochrome b5 Reductase 806C&gt;T Mutation Is Present in the Indigenous Evenk People of Yakutia.
Authors: Tatyana Burtseva, Tatiana Ammosova, Josef T. Prchal, Vyacheslav Chasnyk, Sergei Nekhai, Victor R. Gordeuk
Journal: Blood (2009)
Factors Prognostic for Response and Event Free Survival and Treatment Related Toxicity in 306 Patients with Follicular or Mantle Cell Lymphoma Randomized to Single Agent Rituximab Given at the Standard or at a Prolonged Schedule.
Authors: Michele Ghielmini, Kaspar Rufibach, Gilles Salles, Sergio Cogliatti, Leda Leoncini-Franscini, Claire Leger-Falandry, Martin Fey, Thomas Cerny, Giovanni Martinelli, Rolf Stahel, Andreas Lohri, Nicolas Ketterer, Martin Wernli
Journal: Blood (2004)
AB0591 Nailfold Videocapillaroscopy May Not Reflect Change of Digital Ulcers Status in A Short Term Evaluation of Systemic Sclerosis Patients
Authors: C. Bruni, T. Ngcozana, F. Braschi, T. Barskova, S. Guiducci, S. Bellando-Randone, L. Tofani, C.P. Denton, D.E. Furst, M. Matucci-Cerinic
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Nailfold videocapillaroscopy (NVC) is a useful tool in systemic sclerosis (SSc) patients, useful not only for the diagnosis but also to predict the development of organ and vascular complications, such as the utility of the recently proposed semi-quantitative scoring for digital ulcers (DU) [1]. <h3>Objectives</h3> to prospectively evaluate the change of prevalence of NVC microvascular alterations and their possible correlations with changes in patients-reported outcomes (PROs) and clinical-reported outcomes (CROs) and prevalence of clinical characteristics related to DU in SSc patients. <h3>Methods</h3> SSc patients presenting at least one DU and attending the Rheumatology Wound Care Clinic of the Florence University Hospital or the London Royal Free Hospital were enrolled. Patients were assessed with PROs (HAQ-DI, UKFS, Cochin scale, VAS for pain, DU status and general disease status) and CROs (VAS for DU status) at baseline and after 16 weeks. DU number, appearance of new DU, presence of gangrene, infection, need for hospitalization or surgery procedures, painkillers use were recorded at each visit. NVC was performed at both visit and the presence of micro-haemorrhages, giant capillaries, irregularly enlarged capillaries, ramified capillaries, capillary disorganization and loss of capillaries was scored according to the previously proposed score (0 = no changes, 1 = from 0 to 33%; 2 = from 33% to 66%, 3 = more than 66%). Correlations were tested through Spearman test. <h3>Results</h3> twenty-five SSc patients were eligible for the study. No significant correlation was seen at baseline; when analysing changes between baseline and follow-up, a negative correlation was seen between irregularly enlarged capillaries and the majority of PROs; moreover, changes of number of DU showed negative correlation with changes of giant capillaries, possibly reflecting the evolution of microvascular damage. <h3>Conclusions</h3> NVC is useful tool to predicting DU development, but may not reflect short term change in DU status; therefore a longer-term evaluation may be necessary to detect NVC modifications paralleling DU changes in SSc patients. <h3>References</h3> Smith V., Pizzorni C., De Keyser F, et al. "Validation of the qualitative and semiquantitative assessment of the scleroderma spectrum patterns by nailfold videocapillaroscopy: preliminary results," Arthritis and Rheumatism, vol. 60, pp. S164–S165, 2009. <h3>Disclosure of Interest</h3> None declared
Temporal quantitative phosphoproteomics of ADP stimulation reveals novel central nodes in platelet activation and inhibition
Authors: Florian Beck, Jörg Geiger, Stepan Gambaryan, Fiorella A. Solari, Margherita Dell’Aica, Stefan Loroch, Nadine J. Mattheij, Igor Mindukshev, Oliver Pötz, Kerstin Jurk, Julia M. Burkhart, Christian Fufezan, Johan W. M. Heemskerk, Ulrich Walter, René P. Zahedi, Albert Sickmann
Journal: Blood (2016)
FRI0638-HPR Investigating Plantar Pressure during Walking in Plantar Fasciitis
Authors: R.H. Baris, S. Narin, A. Elvan, M. Erduran
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Plantar fasciitis (PF) is an inflammation of the plantar fascia on the bottom of the foot, characterized by stiffness of medial arch and pain especially during the first steps. It can effect on daily living activities such as walking and a difference in the plantar pressures during walking can be expected (1). But, no studies were found in the literature related to this situation. <h3>Objectives</h3> The aim of this study was to investigate the dynamic plantar pressure during walking and compare the pedography measurements of the affected and unaffected feet of patients with plantar fasciitis during walking. <h3>Methods</h3> Forty patients (28 female, 12 male) with unilateral plantar fasciitis were included in the study. Pain status and functionality was assessed with a visual analog scale (VAS) and Foot Function Index (FFI), respectively. EMED-m pedography platform (Novel GmbH, Germany) was used for dynamic foot plantar pressure measurements. Maximum force, contact area and contact time were measured for total object and hind foot in both affected and unaffected feet. These measures were recorded three times and average values were used in the analysis.The data were not distributed normally and as a result, non-parametric tests were used for interpreting the data. <h3>Results</h3> Average age, height and weight were 51.1 (min-max: 74–33), 165.7 (min-max: 150–190), 82.4 (min-max: 60–110), respectively. VAS was 7.5 (min-max: 6–8) FFI was 55.9 (min-max: 40–63). The results related to pedography measurements were given in Table 1. While, it was observed that hind foot maximum force and contact area were diminished in the affected foot, no differences were found in measures related to total object nor contact time of hind foot. Although a moderate relationship was found between pain status and functionality (rho: 0.57, p&lt;0.001), none of these variables were correlated with pedoghraphy measures (p&gt;0.05). <h3>Conclusions</h3> According to the results of this study, there was a difference in plantar pressures between affected and unaffected feet in plantar fasciitis patients. It seems that the difference is not related to pain status nor functionality. Treatment strategies aiming to resolve this difference might be beneficial to improve outcomes of the treatment. More studies are needed to understand the importance of the dynamic foot pressures during walking in this patient population. <h3>Acknowledgement</h3> 1.Martin RL, Davenport TE, Reischl SF, McPoil TG, Matheson JW, et al. (2014) Heel pain-plantar fasciitis: revision 2014. J Orthop Sports Phys Ther 44: A1–33. <h3>Disclosure of Interest</h3> None declared
Antifungal Prophilaxis with Low Dose Amphotericin B Lipid Complex In Patients with Acute Myeloid Leukaemia: A Single Centre Experience
Authors: Barbara Veggia, Francesca Saltarelli, Enrico Montefusco, Esmeralda Conte, Giusy Antolino, Raffaele Porrini, Bruno Monarca, Antonella Ferrari
Journal: Blood (2011)
Analysis of BCL11A gene Variants in Hematological Malignancies.
Authors: Maria Monne, Giovanna Piras, Antonella Uras, Marco Murineddu, Angelo D. Palmas, Giovanna Pira, Maria Antonietta Fancello, Gian Carlo Latte, Alessandro Murgia, Angelo Novelli, Salvatore Deledda, Attilio Gabbas
Journal: Blood (2009)
Cytoreductive Combined Therapy in Essential Thrombocythemia Patients: Report of the Registro Italiano Trombocitemia (RIT)
Authors: Potito Rosario Scalzulli, Alessia Tieghi, Anna Marina Liberati, Monica Crugnola, Giorgina Specchia, Emma Cacciola, Rosanna Ciancia, Anna Candoni, Enrico Balleari, Roberto Latagliata, Marta Gubbiotti, Maria Rosa Valvano, Lorella Melillo, Nicola Cascavilla, Luigi Gugliotta
Journal: Blood (2008)
Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW
Authors: Stephan Stilgenbauer, Florence Cymbalista, Veronique Leblond, Alain Delmer, Silja Mack, Andreas Bühler, Dirk Winkler, Thorsten Zenz, Raymonde Busch, Stefan Ibach, Sylvain Choquet, Dartigeas Caroline, Bruno Cazin, Olivier Tournilhac, Till M Seiler, Katja Zirlik, Jürgen Alt, Martin Sökler, Johannes Schetelig, Peter Dreger, Michael Hallek, Hartmut Döhner
Journal: Blood (2012)
SAT0339 The Efficacy of The 2015 Eular/acr Recommendations for The Management of Polymyalgia Rheumatica in Japanese Patients
Authors: A. Ueno, Y. Yamamura, K. Fujita, N. Shibutou, M. Yamamura
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Glucocorticoids (GCs) are effective for polymyalgia rheumatica (PMR); however, some patients show inadequate responses to initial GC doses or relapses during GC tapering and develop side effects of GCs. The 2015 EULAR/ACR recommendations for the management of PMR has been proposed very recently, in which early introduction of methotrexate (MTX) in addition to GCs was recommended for such GC-resistance or -intolerance<sup>1)</sup>. Similarly, we have used MTX frequently for PMR patients with relapse, prolonged GC therapy and high risk of GC adverse effects. <h3>Objectives</h3> To examine the efficacy of this 2015 EULAR/ACR recommendation for managing Japanese patients with difficult-to-treat PMR. <h3>Methods</h3> Thirty-five patients were diagnosed with PMR according to the 2012 EULAR/ACR provisional classification criteria for PMR<sup>2)</sup>, including 13 males and 22 females. The average (± SD) age was 69.2 ± 9.4 years; disease duration before therapy 1.9 ± 1.8 months; and the length of observation after starting treatment 23.8 ± 20.7 months. <h3>Results</h3> All patients had active PMR, as demonstrated by high serum CRP levels (6.43 ± 4.50 mg/dL), erythrocyte sedimentation rate (ESR; 85 ± 33 mm/hr) and matrix metalloproteinase-3 (MMP-3; 188 ± 132 ng/mL). All patients with newly-diagnosed PMR were treated first with GCs (starting with the mean dose of prednisolone (PSL) of 15 mg/day; rage 10 - 60 mg/day; 60 mg/day for giant cell arteritis). Twenty-two patients experienced disease relapses, when PSL dose was reduced to 7.1 ± 3.7 mg/day at 7.9 ± 5.8 months. MTX (8.8 ± 3.4 mg/wk) was added in 21 patients and PSL was increased in a patient. Seven patients relapsed after MTX introduction, followed by adding tocilizumab (TCZ) in 6 patients and azathioprine in a patient. One patient with tocilizumab was thereafter switched to adalimumab due to insufficient response to TCZ. At present, PMR became inactive and GC was successfully withdrawn in 8 patients after total 18.0 ± 4.7 month treatment. No significant differences in basal levels of CRP, ESR and MMP-3 was found between GC-response and –resistant patients. Adverse effects included cataract (n=2), diabetes (n=1), metabolic syndrome (n=1), and osteoporosis (n=1). <h3>Conclusions</h3> The results indicate that early addition of MTX for GC-resistance and –intolerance, as recommended by the EULAR/ACR recommendations, may be effective also for Japanese patients, but there are cases refractory to MTX addition, who will require further treatment options including TCZ. <h3>References</h3> Dejaco C, et al. Ann Rheum Dis 2015;74:1799–807. Dasgupta B, et al. Ann Rheum Dis 2012;71:484–92. <h3>Disclosure of Interest</h3> None declared
P1.10: Follow-Up on Results of a Multidisciplinary Team in the Management of Non-Small Cell Lung Cancer in a Developing Country
Authors: Luis Corrales-Rodriguez, Melissa Juárez, Allan Ramos-Esquivel, Manuel Caballero, Mónica Araya, Warner Rodríguez, Andrés Volio, Carlos Zúñiga, René Valladares, Manuel Villalobos, Bruno Solís, Randall Guadamuz, Sofía Antillón, Christian Campos, Tatiana Soto, Adriana Murillo, Alejandro Brenes, Tania Rivera, Luis Rodríguez, Joao Baptista, Zenén Zeledón, Pablo Ordoñez, Ernesto Jiménez, Ileana González
Journal: Journal of Thoracic Oncology (2016)
Dissecting Genetic and Phenotypic Heterogeneity to Map Molecular Phylogenies and Deliver Personalized Outcome and Treatment Predictions in AML
Authors: Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger, Verena I. Gaidzik, Peter Paschka, Michael Heuser, Felicitas Thol, Niccolo Bolli, Arnold Ganser, Konstanze Dohner, Richard F. Schlenk, Hartmut Dohner, Peter J Campbell
Journal: Blood (2015)
Liver and Cardiac Iron Measurements in Very Young Chronically Transfused Patients Show Dangerous Levels of Iron Loading
Authors: Vasilios Berdoukas, Mammen Puliyel, Adam Bush, Thomas Hofstra, Bhakti P. Mehta, Anne Nord, Susan Carson, Tatiana Hernandez, Ani Dongelyan, John C Wood, Thomas D. Coates
Journal: Blood (2011)
Hypoxia Suppresses Arsenic Trioxide-Induced Apoptosis in Human Acute Myeloid Leukemia Cells.
Authors: Yen Ju Yuk, Young Jin Seo, Hyoung Jin Kang, Mi Kyoung Jang, Ji Won Lee, Hye Ry Kim, Eun Jong Han, Hee Young Shin, Hyo Seop Ahn
Journal: Blood (2009)
The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents
Authors: Rajshekhar Chakraborty, Shaji Kumar, Francis Buadi, David Dingli, Angela Dispenzieri, Suzanne R. Hayman, William J Hogan, Prashant Kapoor, Martha Q. Lacy, Nelson Leung, Morie A. Gertz
Journal: Blood (2015)